Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
APS001F + flucytosine
- Development stage
- Unknown
- Lead developer
- Anaeropharma Science
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Small Molecules, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Intravenous (APS001F), Oral (flucytosine)
01
Overview
APS001F + flucytosine is a **combination drug** comprising a living recombinant strain of *Bifidobacterium longum* (APS001F) engineered to express **cytosine deaminase** and the prodrug **flucytosine (5-FC)**. APS001F is administered intravenously, where it localizes to hypoxic regions of solid tumors and produces cytosine deaminase. When flucytosine is given orally, this enzyme converts it locally within the tumor into **5-fluorouracil (5-FU)**, a cytotoxic agent that inhibits tumor growth. This approach is designed to maximize tumor-specific delivery of 5-FU while limiting systemic exposure and toxicity. Preclinical and early clinical trials suggest direct antitumor and local immunomodulatory effects, with development focused on advanced solid tumors[1][3][4][5][7].
- Other names
- APS001F/5-FCflucytosine5-FC
02
Targets
TS (Thymidylate synthase)yCD (Cytosine deaminase (Saccharomyces cerevisiae))
Beyond the preview
Go deeper on APS001F + flucytosine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on APS001F + flucytosine.